blood cancer

News

Sanofi's Darzalex rival hits the mark in phase 3 trial

Johnson & Johnson’s Darzalex multiple myeloma drug has just become a blockbuster – but it could face competition from a rival from Sanofi that has just checked out in a phase 3 trial.

Views & Analysis

Oncology round-up: CAR-T conference raises hopes for solid t...

Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky

News

Doctors and patient groups struggle with CAR-T 'hype'

Managing patients’ expectations of CAR-T therapies is proving to be a huge challenge from when selection decisions are made, through the treatment process and when they are recovering at ho

News

CAR-T firms push to improve manufacturing efficiency

Experience with the approved CAR-T drugs from Novartis and Gilead has shown that being able to manufacture enough products fast enough is a major issue when it comes to marketing these cutt

News

Novartis focusing on cutting CAR-T costs ahead of EU launche...

Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies t

News